Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia.
Jessica L YasudaSteven J StaffaSamuel NurkoMadeline KaneStephanie WallEdward B MougeyJames P FranciosiMichael A ManfrediRachel L RosenPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
Patients with EA are significantly more likely to experience PPI-refractory, non-allergic esophagitis than controls regardless of CYP2C19 metabolizer phenotype, suggesting that factors other than CYP2C19 genetics, including dysmotility, are the primary drivers of esophagitis in EA. CYP2C19 genotype failed to predict PPI-refractory, non-allergic esophagitis in both EA and non-EA children.
Keyphrases